chrisvoncsefalvay/vaers-outcomes huggingface dataset:
shingles 2 months after the shot/ got the shot in May and got shingles in August; shingles/ got the shot in May and got shingles in August; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   In May 2021, the patient received Shingles vaccine. On an unknown date, 2 months after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient received the shot and had Shingles. The patient looked at pictures of others on Google and realized he/she had been blessed with a mild case. The patient stated that the shot helped after all. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were not provided.
This is not an adverse event but rather a medication administration error. He was to get the bivalent Pfizer vaccine but received the monovalent vaccine instead.
This is the second time I have received this vaccine as a "booster". Within two weeks my blood pressure is through the roof and my pulse around 120 with chest pains. I am told this is myocarditis by an ER doc. The state is full of misinforming pinheads that do not take this seriously. Censorship is illegal and not disclosing this data to the public is a liability for these doctors and the government that helps them hide this. IF I GET CHF BECAUSE OF BEING IGNORED I WILL SUE ALL LIABLE PARTIES AND NAME THE DOCTORS, GOVERNMENT, AND THE MANUFACTURER AND WILL ORGANIZE A CLASS ACTION LAWSUIT!!! THANKS TO THE MISINFORMATION AND HIDING THESE ADVERSE EFFECTS NO ONE WILL PUT A SHOT IN THE ARMS OF MY CHILDREN!!!!
After getting the Afluria Flu vaccine, I experienced itching of hands, fingers, feet, legs, neck and back area over several days. I went back to the pharmacy and told the pharmacist and she told me to try an antihistamine. I had already taken Cetirizine Hydrochloride and purchased more on 10/19/2023 and it is helping the itching.
pt started having flu-like sx day p/vax including fever, malaise, gen aching;seen in ER several days later exp peripheral neuropathy of arms & legs;unable to stand;hosp;dx GBS;severe autonomic collapse unable to resuscitate;pt died 31OCT96;
Respiratory disorder; HEADACHE; NAUSEA; VERY EXTREME EXHAUSTION; FEVER; This spontaneous report received from a patient concerned a 71 year old female. The patient's height, and weight were not reported. The patient's past medical history included Addison disease, and concurrent conditions included COPD, Bipolar disorder, Hypothyroidism, Diabetes, and GERD, and other pre-existing medical conditions included the patient had long list of allergy but declined as reporter was in a hurry. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 09-APR-2021, the subject experienced respiratory disorder. On 09-APR-2021, the subject experienced headache. On 09-APR-2021, the subject experienced nausea. On 09-APR-2021, the subject experienced very extreme exhaustion. On 09-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.8 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from respiratory disorder, headache, nausea, very extreme exhaustion, and fever. This report was non-serious.
Fatigue; Pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Fatigue) and VACCINATION SITE PAIN (Pain at injection site) in a 67-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced FATIGUE (Fatigue). On an unknown date, the patient experienced VACCINATION SITE PAIN (Pain at injection site). At the time of the report, FATIGUE (Fatigue) and VACCINATION SITE PAIN (Pain at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication details were not reported by the reporter. Treatment details was not reported by the reporter.
Patient had redness in the injection site. Patients mom noticed white bump on Friday 4-14-17. She also applied bandages to cover up the area.
Information has been received from a health professional concerning her 20 week old niece who, "last week", on approximately 21-AUG-2006 was vaccinated with a first oral dose or rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human-bovine).  Concomitant vaccines included a dose of diphtheria toxoid (+) hepatitis B virus vaccine rHBsAg (yeast) (+) pertussis acellular 3-component (+) poliovirus vaccine inactivated (+) tetanus toxoid (PEDIARIX), a dose of pneumococcal 4 6B 9V 14 18C 19F 23F conj vaccine (CRM197) (PREVNAR) and a dose of Hib conj vaccine (manufacturer unknown).  Subsequently, "last week", on approximately 21-AUG-2006, the patient experienced a fever.  It was reported that the patient recovered.  Unspecified medical attention was sought.  No product quality complaint was involved.  No other information was provided. Additional information is not expected.
Hot to the touch at the injection site; Itchiness at injection site; Swelling at the injection site; Pain on left arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Hot to the touch at the injection site), VACCINATION SITE PRURITUS (Itchiness at injection site), VACCINATION SITE PAIN (Pain on left arm) and VACCINATION SITE ERYTHEMA (Swelling at the injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for an unknown indication.     Concurrent medical conditions included Type 2 diabetes mellitus and Asthma.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced VACCINATION SITE PAIN (Pain on left arm). On 17-Mar-2021, the patient experienced VACCINATION SITE WARMTH (Hot to the touch at the injection site), VACCINATION SITE PRURITUS (Itchiness at injection site) and VACCINATION SITE ERYTHEMA (Swelling at the injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) at a dose of UNK dosage form. At the time of the report, VACCINATION SITE WARMTH (Hot to the touch at the injection site), VACCINATION SITE PRURITUS (Itchiness at injection site), VACCINATION SITE PAIN (Pain on left arm) and VACCINATION SITE ERYTHEMA (Swelling at the injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products included medications for type 2 diabetes, asthma and blood pressure (name unspecified).  Treatment included ice pack.
Extreme anxiety, nausea, dehydration, dry mouth, chills, tightness in chest, sore muscles in legs, tiredness, dizziness, brain fogginess
Felt like she was going to faint, nausea, stomach pain, felt hot. Observed and called paramedics. They took charge of her and took her to hospital. She came back to the pharmacy later in the afternoon and said her blood pressure had dropped very low. She was fine when she came back and thanked us for helping.
Fever, chills, nausea, fatigue, headache. Took Aleve and rested all day.
Chest pain after one week of injection from vaccine.  Patient has had continuous chest pain since vaccine.  Patient was admitted to emergency room on 7/9 for chest pain.  Examination came back normal.  Stress test was conducted 8/17.  Stress test showed normal results.  Doctors are unsure of what is causing chest discomfort.  No shortness of breath.  Just a constant pain in center of chest, sometimes migrating to left or right side.  No history of acid reflux.  Patient has a family history of heart disease.  Patient is not overweight and lives an active, relatively healthy lifestyle.
PATIENT STATES INSIDE ARM AND COLLAR BONE AREA INFLAMMED AND REAL SORE. RECIEVED FLUVIRIN AND PNEUMOCOCCAL VACCINE IN SAME ARM. PATIENT STATES SHE IS FINE JUST REAL SORE
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old male patient received BNT162b2 (BNT162B2), on 24Mar2021 as dose number unknown, single (Lot number: ER8733) and on 14Apr2021 as dose number unknown, single (Lot number: EW0158) at the age of 34 years for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 15May2022, outcome "recovering" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive, notes: After taking the entire course of paxlovid, I felt better, but a couple days later I started getting symptoms again and tested positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course of the events: Other medication in 2weeks: Yes. Adverse event: Patient had a bitter taste in my mouth after taking Paxlovid. After taking the entire course of Paxlovid, patient felt better, but a couple days later started getting symptoms again and tested positive. Adverse event start date: 15May2022. Patient recovered: Recovering.  No follow-up attempts are possible. No further information is expected.
Patient states immediately after shot, she felt itchy and tenderness at the site. Later in evening the discomfort worsened and area became swollen. Also reports weakness and numbness felt on her neck through fingertips.
Suffered blood clotting leading to three strokes. Started with numbness in limbs and face on 3/5 at 8:30AM and led to Ischemic stroke in three parts of the brain.
Pfizer 2/9/21 Lot# EL9269;  Pfizer 3/2/21 Lot# EN6202;  Pfizer 11/6/21 Lot# FH8020
experienced loss of taste; Cannot taste or smell red wine vinegar or bleach respectively.; This is a spontaneous report from a contactable other healthcare professional. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 20Dec2020 at a single dose for COVID-19 immunization. The patient's medical history includes wears a CPAP (ongoing). Concomitant medications were not reported. The patient received vaccine 20Dec2020 and experienced loss of taste. He wears a CPAP. He went to the doctor on 21Dec2020 and was prescribed amoxicillin. The patient cannot taste or smell red wine vinegar or bleach respectivel. Outcome of the events was unknown.   Information on Lot/Batch has been requested.
10/24 Presented to MD with fever, chills, headache and lower extremities pain, sore throat. Treated as viral gave Motrin. 10/25 symptoms worse patient admitted to hospital.  11/30/07 Reviewed hospital medical records which reveal patient experienced fever & HA x 2 days.  Exam revealed erythemic posterior pharynx.  Admitted 10/25-10/27/2007.  Tx w/IV antibiotics & decongestants.  Symptoms resolved, labs returned to normal & d/c to home on continued oral antibiotics & decongestant. FINAL DX: Fever of unknown origin.
Heart Palpitations; Heart rate increased; couldn't sleep the night; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart Palpitations), HEART RATE INCREASED (Heart rate increased) and INSOMNIA (couldn't sleep the night) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 11-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Apr-2021, the patient experienced PALPITATIONS (Heart Palpitations), HEART RATE INCREASED (Heart rate increased) and INSOMNIA (couldn't sleep the night). At the time of the report, PALPITATIONS (Heart Palpitations), HEART RATE INCREASED (Heart rate increased) and INSOMNIA (couldn't sleep the night) outcome was unknown.            Concomitant medications included birth control, vitamins and supplements.
I received a Shingles vaccine 03/03/2021 dose two. 02/17/2021 and 03/18/2021 Covid-19 vaccine. I had bloodwork done which I do regularly on 03/29/2021. My results showed my Vitamin D level was 5.5 which is extremely low. It was less than two weeks after the second dose of the Covid-19 vaccine. I was prescribed a prescription for Vitamin D. After three weeks I discontinued the medication due to dizziness. I have never had low levels of Vitamin D before.
Extremely heavy menstrual flow - super absorbent leaking after 2 hours - Ongoing - currently day 2
RN reports call describing red itchy upper arm near injection site for Td given 10 days prior to call.
bilatral inguneal enlargement more on the left side; CBC, ESR, PPD CXR all WNL;
Pt's right arm bled, felt like it hit bone. About 6 hours after, the pt's arm itched, felt hot, and hurt. This continued for about 24 hours. No medical treatment sought, no fever.
ERYTHEMATOUS AREA SURROUNDING INJECTION SITE ON LEFT THIGH AREA.
Lymph node under chin, under right underarm, groin area, both legs and feet swollen painful and tightness.
severe swelling & tenderness of upper lt arm;8cm rash;arm was so sore that was unable to use & perform duty as plane navigator, so did not work for 24hr;site of rxn was anthrax site, not typhoid site;
Patient reported redness, warmth, & raised spot around injection site occurring 10 days after vaccination.
Patient started to notice a large welt/knot from her left shoulder 3/4 down to her elbow. Welt raised with redness. She did not feel sick - this started the evening of Feb 5th. Next day - 2/6/13 the redness peaks on Lt. arm Pt. iced arm & took ADVIL & a BENADRYL per Dr. on 2/7 Pt. states feeling cold with chills all day. Lt. upper arm improving slowly Pt. states still has uncomfortable feeling & now has itching but no numbness or tingling down arm. Pt. called reporting reaction & advised to come in for Dr. visit 2/8.
Severe vomiting and diarrhea for 12 hours.  Received shot at center.  Called at noon on 3/10 and got prescribed  ONdansetron 4MG.  The vomiting stopped about an hour later.  Am still weak this morning.   VERY concerned about getting second shot.
NEW HIRE EMPLOYEE RECEIVED HEPATITIS B VACCINE ON 05/17/2023. INJECTION SITE IS LEFT DELTOID. SHE DENIED ANY ADVERSE REACTION AFTER 15 MINUTES OF REST.  EMPLOYEE REPORTS THAT SHE FELT SLIGHT ITCHINESS AND TENDERNESS ON THE INJECTION SITE, ON THE EVENING OF 05/18/2023 BUT, "DID NOT THINK ANYTHING OF IT". SHE REPORTS THAT ON THE MORNING OF 05/19/2023, SHE FELT INJECTION SITE SLIGHTLY ITCHY, SITE FELT RAISED, AND WARM TO TOUCH. SHE REPORTS THAT LEFT SHOULDER IS TENDER TO MOVE, AND  PAIN RATED AT 2 (10 BEING THE HIGHEST). WRITER VIEWED INJECTION SITE, WHICH LOOKS RED AND SLIGHTLY RAISED, MEASURING AT 2X1.5 INCHES IN DIAMETER. EMPLOYEE DENIED ANY OTHER SYMPTOMS AT THIS TIME.
2 family's members of hers died after receiving the Pfizer BioNtech covid 19 vaccine; This is a spontaneous report from a non-contactable consumer. A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Reporter's 2 family's members of hers died after receiving the pfizer biontech covid 19 vaccine on an unspecified date. The patient died on an unspecified date.  It was not reported if an autopsy was performed.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Reported Cause(s) of Death: 2 family's members of hers died
This case was reported by a healthcare professional and described the occurrence of injection site pain in a 50-year-old male subject who was vaccinated with Flulaval (GlaxoSmithKline) for prophylaxis.  On 11 October 2007 the subject received 1st dose of Flulaval (.5 ml, unknown, right arm).  On 21 October 2007, 10 days after vaccination with Flulaval, the subject experienced injection site pain.  At the time of reporting the event was unresolved.
rash in the injection site; rash in the abdomen area/Rash could be a herpes zoster rash; This case was reported by a pharmacist via call center representative and described the occurrence of injection site rash in a 55-year-old male patient who received Herpes zoster (Shingrix) (batch number 7bc47, expiry date 9th June 2023) for prophylaxis.   On 14th July 2022, the patient received the 1st dose of Shingrix. On 19th July 2022, 5 days after receiving Shingrix, the patient experienced injection site rash and vesicular rash. On 19th July 2022, the outcome of the injection site rash and vesicular rash were recovered/resolved.   It was unknown if the reporter considered the injection site rash and vesicular rash to be related to Shingrix.     Additional Information: GSK receipt date:01-Aug- 2022 Reporters comment:  The patient developed rash in the abdomen area and in the injection site. The reporter consented for follow-up. Rash could be a herpes zoster rash. Additional Supportive information: The HCP mentioned that he was not sure if the rash was herpes zoster, herpes zoster was not considered.
Redness, swelling of arm (pneumonia site), nausea, headache, achiness all over general malaise.
Cold symptoms; Drug ineffective; Positive rapid COVID test on 18Nov2021; Booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-healthcare professional). The reporter is the patient. A 68 year-old male patient received bnt162b2 (COMIRNATY), administration date 24Aug2021 (Batch/Lot number: Unknown) at the age of 68 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "High Blood Pressure." (unspecified if ongoing). The patient concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, Manufacturer unknown) for COVID-19 immunisation, Covid-19 vaccine (Dose 2, Manufacturer unknown) for COVID-19 immunisation. The following information was reported: IMMUNISATION (medically significant) with onset 24Aug2021, outcome "unknown", described as "Booster", DRUG INEFFECTIVE (medically significant) with onset 18Nov2021, outcome "unknown", described as "drug ineffective", COVID-19 (medically significant) with onset 18Nov2021, outcome "unknown", described as "positive rapid COVID test on 18Nov2021", NASOPHARYNGITIS (medically significant), outcome "unknown", described as "cold symptoms". The patient underwent the following laboratory tests and procedures: sars-cov-2 antibody test: (18Nov2021) positive.  No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Expired vaccine used; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 26-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 525NP, expiry date 4th September 2021) for prophylaxis.   On 6th September 2021, the patient received Boostrix. On 6th September 2021, unknown after receiving Boostrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.  Additional details were provided are as follows: Nurse reported that, the patient received expired boostrix vaccine, which led to expired vaccine used. The reporter consented to follow-up.
Diarrhea, 5-6 liquid stools daily continuing for three weeks (this occurred after first dose at 2 months as well).
12/7/1999:Rcv'd DTaP,IPV & Hib vax.12/8/99:pt crying alot, cranky,will not suck his bottle.12/13/99:pt hospitalized w/ irritability,lethargy,refusal to eat,dehydration.Dx'd w/ pyloric stenosis & reflux;stenosis corrected w/surgery.
Hospitalized 10/17/2021; COVID-19 positive 10/17/2021; fully vaccinated  BRIEF OVERVIEW: Hematologist/Oncologist: No care team member to display Admission Date: 10/17/2021 Discharge Date: 10/21/21   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: COVID-19    HOSPITAL COURSE: No notes on file   This is a 66 y.o. patient with a past medical history significant for HTN, CAD, Atrial Fibrillation, Depression, DM type II, neuropathy associated with MM, HLD and Multiple myeloma who presented with symptoms of weakness and near syncope at home per spouse at bedside 10/17/21. In the ED, patient was found to be hypoxic and nauseous, and improved with 2 L NC and Zofran. A CXR revealed patchy diffuse bilateral airspace opacities, compatible with COVID 19 pneumonia and his lactic acid ws slightly elevated, covid swab was positive. Patient was admitted for further tx. ID followed. Patient was placed on dexamethasone 6 mg daily, Remdesevir, and monoclonal antibodies given 10/18/21. Weaned off 2L to RA. MRI of lumbar/sacrum 10/18/21 no aggressive focal lesions, no fracture or mass. Mild progressive facet arthropathy L3-4. Multilevel lumbar spondylosis. PT/OT evaluated while inpatient. Patient also had coffee - ground emesis 10/18/21, GI followed. Protonix gtt started -- transitioned to PPI PO BID for 8 weeks, then will have EGD on outpatient basis when covid pna resolves. Eliquis initially held, then restarted as hgb stayed stable.  Also noted hyperbilirubinemia 10/17 of 1.9 and had RUQ US which showed hepatic steatosis and mild splenomegaly, no biliary tree dilation. While inpatient team followed and adjusted insulin tx.
Numbness in forehead, Headache and metallic taste in the mouth. Event only lasted about 30 seconds to 1 minute. After that event went away.
Pt developed red area to injection site, fever, and swollen lymph node to groin area.
Pt developed chickenpox-modified about 20-25 pox 05/01/04.